Quince Therapeutics Inc (QNCX)

$1.68 0.00 (N/A)
Market Cap 90.24M
Revenue (ttm) 0.00
Net Income (ttm) -56.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.45
Volume 290,500
Avg Vol 357,558
Day's Range N/A - N/A
Shares Out 53.71M
Stochastic %K 60%
Beta 1.07
Analysts Strong Sell
Price Target $7.40

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 910 5717
Address:
611 Gateway Boulevard, Suite 273, South San Francisco, United States
RunningRobert1
RunningRobert1 Nov. 14 at 6:48 PM
$QNCX Quince Therapeutics QNCX 3Q 2025 Summary 14Nov2025 https://youtu.be/m8_2xzTGKcQ Overall one of my targets for 2026, the company has enough cash to get to data, and thats what we are looking at, most likely we will see some kind of run up to data in early 2026
0 · Reply
ADSlay
ADSlay Nov. 14 at 12:41 AM
$QNCX 🚨🚨🚨🚨🚨 Marshall Wace initiated a NEW position in $QNCX Wow $98 billion AUM 🚀🚀🚀🚀🚀
2 · Reply
ADSlay
ADSlay Nov. 13 at 3:58 PM
$QNCX Despite 24% Discontinuation Rate (vs 3.8% now) and 26% Missing data (vs 6% now) in previous ph3 ATTeST trial, mITT p was still 0.07. That's quarter of missing data and discontinuation, and to still be able to hit 0.07, is remarkable in itself. This is objective data. No pump.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 2:02 PM
D. Boral Capital has adjusted their stance on Quince Therapeutics ( $QNCX ), setting the rating to Buy with a target price of 4.
0 · Reply
ConfidencePotato
ConfidencePotato Nov. 13 at 6:14 AM
$QNCX
1 · Reply
ADSlay
ADSlay Nov. 12 at 9:33 PM
$QNCX 100% is quite the number of OLE rollovers. It says everything without saying anything.
0 · Reply
QNCXtothemoon
QNCXtothemoon Nov. 12 at 9:17 PM
$QNCX https://ir.quincetx.com/node/9616/html
0 · Reply
QNCXtothemoon
QNCXtothemoon Nov. 12 at 9:16 PM
$QNCX https://ir.quincetx.com/node/9611/html#qncx-ex99_1.htm
0 · Reply
Eureka3
Eureka3 Nov. 12 at 5:03 PM
$QNCX Too many ups and downs. Not good imo. Something is cooking.
1 · Reply
ConfidencePotato
ConfidencePotato Nov. 12 at 5:00 PM
$QNCX did they publish earnings?
0 · Reply
Latest News on QNCX
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:05 PM EST - 2 days ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Nov 10, 2025, 4:05 PM EST - 4 days ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 9, 2025, 4:05 PM EDT - 5 weeks ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript

Oct 2, 2025, 5:12 PM EDT - 6 weeks ago

Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 25, 2025, 4:05 PM EDT - 7 weeks ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Quince Therapeutics, Inc. - Special Call

Sep 24, 2025, 1:13 AM EDT - 7 weeks ago

Quince Therapeutics, Inc. - Special Call

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 11, 2025, 4:05 PM EDT - 2 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 2 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:05 PM EDT - 3 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Aug 7, 2025, 8:00 AM EDT - 3 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 16, 2025, 8:00 AM EDT - 4 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jul 10, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 25, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 18, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 5 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jun 3, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 15, 2025, 9:50 AM EDT - 6 months ago

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 6 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 30, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Apr 3, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Mar 24, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 7, 2025, 8:00 AM EST - 10 months ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 10 months ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Feb 4, 2025, 4:05 PM EST - 10 months ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 10 months ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 10 months ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Jan 23, 2025, 4:05 PM EST - 10 months ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics to Participate at Upcoming Investor Conferences

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 19, 2024, 9:16 PM EDT - 1 year ago

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

May 6, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics Launches Scientific Advisory Board

Feb 22, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Launches Scientific Advisory Board

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 15, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Quince Therapeutics to Participate at Investor Events in January 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Sep 28, 2023, 4:05 PM EDT - 2 years ago

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.

Jul 13, 2023, 8:00 AM EDT - 2 years ago

Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.

RunningRobert1
RunningRobert1 Nov. 14 at 6:48 PM
$QNCX Quince Therapeutics QNCX 3Q 2025 Summary 14Nov2025 https://youtu.be/m8_2xzTGKcQ Overall one of my targets for 2026, the company has enough cash to get to data, and thats what we are looking at, most likely we will see some kind of run up to data in early 2026
0 · Reply
ADSlay
ADSlay Nov. 14 at 12:41 AM
$QNCX 🚨🚨🚨🚨🚨 Marshall Wace initiated a NEW position in $QNCX Wow $98 billion AUM 🚀🚀🚀🚀🚀
2 · Reply
ADSlay
ADSlay Nov. 13 at 3:58 PM
$QNCX Despite 24% Discontinuation Rate (vs 3.8% now) and 26% Missing data (vs 6% now) in previous ph3 ATTeST trial, mITT p was still 0.07. That's quarter of missing data and discontinuation, and to still be able to hit 0.07, is remarkable in itself. This is objective data. No pump.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 2:02 PM
D. Boral Capital has adjusted their stance on Quince Therapeutics ( $QNCX ), setting the rating to Buy with a target price of 4.
0 · Reply
ConfidencePotato
ConfidencePotato Nov. 13 at 6:14 AM
$QNCX
1 · Reply
ADSlay
ADSlay Nov. 12 at 9:33 PM
$QNCX 100% is quite the number of OLE rollovers. It says everything without saying anything.
0 · Reply
QNCXtothemoon
QNCXtothemoon Nov. 12 at 9:17 PM
$QNCX https://ir.quincetx.com/node/9616/html
0 · Reply
QNCXtothemoon
QNCXtothemoon Nov. 12 at 9:16 PM
$QNCX https://ir.quincetx.com/node/9611/html#qncx-ex99_1.htm
0 · Reply
Eureka3
Eureka3 Nov. 12 at 5:03 PM
$QNCX Too many ups and downs. Not good imo. Something is cooking.
1 · Reply
ConfidencePotato
ConfidencePotato Nov. 12 at 5:00 PM
$QNCX did they publish earnings?
0 · Reply
Tryitin
Tryitin Nov. 11 at 9:23 PM
$QNCX What did I say....Fkin fantastic move on my large shares. Thanks Shorts.
0 · Reply
ConfidencePotato
ConfidencePotato Nov. 11 at 9:00 PM
$QNCX strong close
0 · Reply
Westieofwallst
Westieofwallst Nov. 11 at 8:42 PM
$QNCX
2 · Reply
bullval1
bullval1 Nov. 11 at 8:24 PM
$QNCX incredible bargain here now considering the potential revenue/application possibilities
0 · Reply
ConfidencePotato
ConfidencePotato Nov. 11 at 4:18 PM
$QNCX what’s your best guestimate for earning tomorrow?
1 · Reply
Barryman1
Barryman1 Nov. 11 at 3:45 PM
$QNCX no price increase after the good news? Accumulation time 🔥🔥⤴️
2 · Reply
Eureka3
Eureka3 Nov. 11 at 2:52 PM
$QNCX What's happening here ?
1 · Reply
Tryitin
Tryitin Nov. 11 at 2:44 PM
$QNCX 1 year daily chart indicates 1.44 as strong support and no wonder it reversed from there. Lets see how far this reverse. 1.8 thru 1.9 retest possible in the next day or two.
0 · Reply
Westieofwallst
Westieofwallst Nov. 11 at 2:35 PM
$QNCX
0 · Reply
dv1809
dv1809 Nov. 11 at 2:28 PM
$QNCX yesssssssss
0 · Reply
BearTamerTrading
BearTamerTrading Nov. 11 at 3:54 AM
🚀 After-Hours Momentum — Bear Tamer Trading Community Wins 🔥 Part 1/2 The following tickers moved sharply in the after-hours session thanks to breaking catalysts and momentum continuation from earlier alerts: 🔥 $SLRX — Strength on low float momentum after earlier pharma activity 🔥 $CMTL — Profit-taking continues after recent contract headlines 🔥 $QNCX — Light liquidity + spec accumulation after steady-day consolidation 🔥 $CYCN — Surged after positive nitrate therapeutics update and volume spike Members were already in position due to timely squawk alerts 💪 If you missed it, watch the replay for proof ⬇️ 🎥 Watch the Replay: https://www.youtube.com/live/Bw-au0_c-Uk?si=AStYA0c19wSLmRMd
1 · Reply
ADSlay
ADSlay Nov. 11 at 12:05 AM
$QNCX "Are these reviews even worth it", I asked (you should too) $QNCX will surprise us all Dirk, Charles and Brandon are a formidable trio on a mission. Look how they got us $OPCH partnership. We will be sipping colored-umbrella mai tais by the ocean in 2026. Watch!
1 · Reply